BioXcel Therapeutics Inc
BTAI
View Detailed Chart
1.500USD
+0.130+9.49%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
29.99MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+9.49%
5 Days
-5.66%
1 Month
-13.79%
6 Months
-54.82%
Year to Date
-6.25%
1 Year
-49.76%
View Detailed Chart
TradingKey Stock Score of BioXcel Therapeutics Inc
Currency: USD Updated: 2026-02-06Key Insights
BioXcel Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 122 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.60.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioXcel Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
BioXcel Therapeutics Inc Highlights
StrengthsRisks
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 504.27% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.27M.
Overvalued
The company’s latest PE is -0.00, at a high 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 292.75K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.27.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
14.600
Target Price
+965.69%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
BioXcel Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
BioXcel Therapeutics Inc Info
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Ticker SymbolBTAI
CompanyBioXcel Therapeutics Inc
CEOMehta (Vimal)
Websitehttps://www.bioxceltherapeutics.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
67596.500
-2373.630 (-3.39%)
282.580
+22.390 (+8.61%)
2002.090
-49.640 (-2.42%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
